Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
BMS-J&J blood thinner fails phase 3, denting blockbuster hopes
The partners stopped the phase 3 early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.
Nick Paul Taylor
Nov 14, 2025 8:10am
Novartis' resistance-busting malaria drug hits phase 3 goal
Nov 13, 2025 7:05am
Alkermes races to phase 3 after posting another narcolepsy win
Nov 12, 2025 9:30am
Novo Nordisk shares mixed data behind pivotal heart disease push
Nov 11, 2025 8:32am
Cogent eyes FDA approval after clearing another ph. 3 hurdle
Nov 10, 2025 10:57am
Roche reports phase 3 multiple sclerosis wins for BTK inhibitor
Nov 10, 2025 6:26am
